Pulmotect Initiates Landmark Phase 2 Clinical Trial in Immunosuppressed Cancer Patients
Leading oncology centers in the United States engaged to conduct the Phase 2 Antiviral Trial and further advance the development of PUL-042 HOUSTON, TX, UNITED STATES, July 8, 2025 /EINPresswire.com/ -- Pulmotect, Inc., a privately held clinical …